Ann: PTX data demonstrates key OmniCAR features in next gen CAR-T, page-77

I am unfamiliar with the "masking tech" platform and whether it is drugs based or a treatment platform like PTX's OmniCAR, or whether it is a competitor, but agree with the basics that the big drug companies are out for the dollars rather than patients.
Yes, it is possible that a major drug Co could try to close OmniCAR down by buying PTX at a price - but that will only be for the platform. There are going to be hundreds of the small 'me too' biotech Co's continuing with the binders research to marry with CAR-T that would remain a pain in their butt for decades.

I see SYC's vision for a one stop shop for the platform, the binders and the cell enhancement as a way of making it difficult to close down a treatment system versus the old relative poor drug and radiation systems that the FDA is allowing in the absence of something better.
IMO the cat is already out of the bag with OmniCAR and any major Co that tried to close it down with a single or multiple buy-out would be committing financial and political suicide.

As long as the FDA can get some expected excellent efficacy results from OmniCAR in a few years, some of the current drug based systems and some radiation treatments approvals will be progressively rescinded - and that will be a pain for them - so yes, expect some backlash.
Hence, IMO, any buy-out would be to enhance profits by trying to take over world rights ASAP to lead the pack and I think that would be unlikely until FDA approval is obtained from the current optimization work to permit the initial OmniCAR trial work in 2023?

But again IMO unlikely, for these treatment systems need to be handled by specialist hospital systems covering pathology, T-cell enhancement/growth or its manufactured alternative and the various binders that may be needed for each patient - and all with their separate licensing/IP rights with PTX supplying the platform and some of the cell growth/enhancement work only. A company trying to control the lot would have to buy the lot - otherwise just try and control and profit from the platform part - just as PTX plans to do.
It as a paradigm shift from researching, producing and selling single drugs under a patent system to licensing/collaborating/partnering a treatment platform that can be patient specific with alternatives - all beyond control of the platform or the binder owner

This to me is the current PTX - OmniCAR moat - a platform that is controllable and flexible to be used for any cell type or binder for many cancers with possibilities for use with other diseases as well. it may take decades to find the best binders for all cancers or their mutations and there may be some competitive systems - but I doubt they could be more advantageous than OmniCAR with the only real competition being price IF they can completely match OmniCAR at all.

What I/we do not know is the licensing value or rights for Penn State and Oxford - how long do they last, value per treatment for them and PTX per patient. When do the patents run out? Etc. And that will start to be discussed/become evident when the licensing/partnership deals start?

Anyway, if there is a buy-out I will be holding out for a monster price. No piddling $1 or $2 billion. It could not be done quietly or without competition bids.

Have a merry Xmas and expect a good PTX 2022 ... at some stage.